Characterizing the molecular and spatial heterogeneity of midline gliomas in adults: a single institution analysis
Journal of Neuro-Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 6, 2025
Language: Английский
Liquid biopsies for the monitoring of gliomas and brain metastases in adults
Acta Neuropathologica,
Journal Year:
2025,
Volume and Issue:
149(1)
Published: April 26, 2025
Abstract
Clinical
evaluation
and
MR
imaging
are
currently
the
cornerstone
of
brain
tumor
progression
monitoring.
However,
this
is
complicated
by
occurrence
treatment
effects
such
as
pseudoprogression
radionecrosis.
While
essential
for
patient
management,
distinction
from
true
remains
a
significant
challenge.
Moreover,
provides
limited
real-time
insights
into
heterogeneity,
genetic
divergence,
resistance.
Although
surgical
histopathological
biopsies
can
yield
additional
valuable
information,
they
not
always
conclusive,
invasive,
therefore,
suitable
longitudinal
measurements.
In
era
precision
medicine,
there
critical
need
minimally
accurate,
cost-effective
monitoring
methods
both
primary
tumors
metastases.
Liquid
have
emerged
potential
candidate.
Various
analytes,
including
circulating
nucleic
acids,
extracellular
vesicles,
platelet
RNAs,
cells,
be
obtained
whole
blood
its
derivatives,
well
other
body
fluids
cerebrospinal
fluid.
narrative
review,
we
outline
liquid
management
gliomas
metastases
in
adults
emphasize
their
utility
disease
response.
We
discuss
most
studied
biofluids
along
with
respective
advantages
downsides.
Furthermore,
address
key
considerations
future
research
biobanking
to
pave
way
clinical
implementation.
Language: Английский
A field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery
Neuro-Oncology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 27, 2024
Abstract
BACKGROUND
While
serial
sampling
of
glioma
tissue
is
rarely
performed
prior
to
recurrence,
cerebrospinal
fluid
(CSF)
an
underutilized
longitudinal
source
candidate
biomarkers
for
understanding
therapeutic
impacts.
However,
the
impact
key
variables
consider
in
CSF
samples
monitoring
biomarker
discovery,
including
anatomical
location
and
post-surgical
changes,
remains
unknown.
METHODS
Aptamer-based
proteomics
was
on
147
from
74
patients,
71
whom
had
grade
2-4
astrocytomas
or
2-3
oligodendrogliomas.
This
included
pre-
versus
post-resection
intracranial
obtained
at
early
(1-16
days;
n=20
patients)
delayed
(86-153
n=11
timepoints
patients
with
glioma.
Paired
lumbar-versus-intracranial
were
also
(n=14
patients).
RESULTS
Significant
differences
identified
proteome
between
lumbar,
subarachnoid,
ventricular
gliomas.
Importantly,
we
found
that
resection
a
significant,
evolving
proteome,
distinct
sets
proteins
present
different
since
resection.
Our
analysis
suggests
potential
disease
evaluation
pharmacodynamic
targeted
therapies,
such
as
bevacizumab
immunotherapies.
CONCLUSIONS
The
serves
rich
dynamic
reservoir
can
be
used
evaluate
effects
other
therapies
over
time.
All
data
within
this
study,
detailed
individual
clinical
annotations,
are
shared
resource
neuro-oncology
community
collectively
address
these
unanswered
questions
further
understand
biology
through
proteomics.
Language: Английский
A Hitchhiker’s Guide Toward CSF Biomarkers for Neuro-Oncology
Neuro-Oncology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 27, 2024
Cerebrospinal
fluid
(CSF)
has
emerged
as
a
valuable
liquid
biopsy
source
for
glioma
biomarker
discovery
and
validation.
CSF
produced
within
the
ventricles
circulates
through
subarachnoid
space,
where
composition
of
glioma-derived
analytes
is
influenced
by
proximity
anatomical
location
sampling
relative
to
tumor,
in
addition
underlying
tumor
biology.
The
substantial
gradients
observed
between
lumbar
intracranial
compartments
tumor-derived
underscore
importance
site
selection.
Moreover,
radiographic
features,
such
tumor-CSF
contact
blood-brain
barrier
(BBB)
disruption,
are
critical
covariates
that
may
affect
detectability
abundance
plasma-derived
CSF,
respectively.
Longitudinal
sampling,
enabled
access
devices
like
Ommaya
reservoirs,
offer
window
into
treatment
response
disease
progression,
though
variability
analyte
yield,
sample
volumes,
dynamic
effects
surgical
resection
pose
challenges.
This
review
critically
evaluates
anatomic,
radiographic,
longitudinal
factors
impact
abundance.
Practical
considerations
biobanking,
including
device
placement
collection,
also
reviewed.
Key
takeaways
recommendations
validation
provided
based
on
our
collective
experience,
along
with
resources
investigators
aiming
develop
biobanking
at
their
institutions.
Language: Английский